Literature DB >> 21606945

HIV-specific CD8+ T-cell proliferation is prospectively associated with delayed disease progression.

Lyle R McKinnon1, Rupert Kaul, Joshua Kimani, Nico J Nagelkerke, Charles Wachihi, Keith R Fowke, Terry Blake Ball, Francis A Plummer.   

Abstract

Human immunodeficiency virus (HIV)-specific CD8(+) T-cell proliferation is consistently correlated with enhanced host HIV immune control, but whether proliferative responses are a cause or consequence of immune protection is unclear. We measured Env-specific CD8(+) T-cell proliferation and interferon (IFN)-γ secretion in HIV-infected participants with CD4 counts >200, who then completed 121 person-years of prospective follow-up to monitor HIV disease progression. In all, 13 of 31 participants (42%) reached end point during longitudinal follow-up. Strong Env-specific CD8(+) T-cell proliferation (>10% of CD8(+) T cells) was observed in 14/31 participants at baseline, and this was associated with a longer time to HIV disease progression end point, stratified baseline CD4 count (P=0.016). No associations were observed for IFN-γ ELISPOT responses and progression (P>0.2). Strong proliferation remained significant in multivariate Cox regression analyses (P=0.044) as an independent predictor of delayed HIV disease progression, along with baseline CD4 count (P=0.04). Duration of HIV infection was associated with more rapid progression in univariate, but not multivariate, analysis (P=0.112). Age and baseline viral load were not predictive of progression. HIV-specific CD8(+) T-cell proliferation was a correlate of protective immunity in this prospective study; such responses may be important for HIV vaccine protection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606945     DOI: 10.1038/icb.2011.44

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  10 in total

1.  Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells.

Authors:  Son Nguyen; Claire Deleage; Samuel Darko; Amy Ransier; Duc P Truong; Divyansh Agarwal; Alberto Sada Japp; Vincent H Wu; Leticia Kuri-Cervantes; Mohamed Abdel-Mohsen; Perla M Del Rio Estrada; Yuria Ablanedo-Terrazas; Emma Gostick; James A Hoxie; Nancy R Zhang; Ali Naji; Gustavo Reyes-Terán; Jacob D Estes; David A Price; Daniel C Douek; Steven G Deeks; Marcus Buggert; Michael R Betts
Journal:  Sci Transl Med       Date:  2019-12-18       Impact factor: 17.956

2.  T Regulatory Cell Induced Foxp3 Binds the IL2, IFNγ, and TNFα Promoters in Virus-Specific CD8+ T Cells from Feline Immunodeficiency Virus Infected Cats.

Authors:  Yan Wang; Mukta Nag; Joanne L Tuohy; Kristina De Paris; Jonathan E Fogle
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11-17       Impact factor: 2.205

3.  Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis.

Authors:  Gaurav D Gaiha; Kevin J McKim; Matthew Woods; Thomas Pertel; Janine Rohrbach; Natasha Barteneva; Christopher R Chin; Dongfang Liu; Damien Z Soghoian; Kevin Cesa; Shannon Wilton; Michael T Waring; Adam Chicoine; Travis Doering; E John Wherry; Daniel E Kaufmann; Mathias Lichterfeld; Abraham L Brass; Bruce D Walker
Journal:  Immunity       Date:  2014-12-08       Impact factor: 31.745

4.  Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.

Authors:  Missa P Sanou; Shannon R Roff; Antony Mennella; John W Sleasman; Mobeen H Rathore; Janet K Yamamoto; Jay A Levy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

5.  Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway.

Authors:  Rong Wang; Aizhang Xu; Xueying Zhang; Jie Wu; Andrew Freywald; Jianqing Xu; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

Review 6.  Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.

Authors:  Marcel Tongo; Wendy A Burgers
Journal:  Viruses       Date:  2014-10-23       Impact factor: 5.048

7.  HIV-Specific CD8+ T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid Tissue.

Authors:  Morgan A Reuter; Perla M Del Rio Estrada; Marcus Buggert; Constantinos Petrovas; Sara Ferrando-Martinez; Son Nguyen; Alberto Sada Japp; Yuria Ablanedo-Terrazas; Amaranta Rivero-Arrieta; Leticia Kuri-Cervantes; Heidi M Gunzelman; Emma Gostick; David A Price; Richard A Koup; Ali Naji; David H Canaday; Gustavo Reyes-Terán; Michael R Betts
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

8.  T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell.

Authors:  Sai Liu; Jianping Sun; Zhen Li; Ling Qin; Guihai Liu; Kang Li; Hao Wu; Tao Dong; Yonghong Zhang
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

9.  IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses.

Authors:  Jun Liu; Wei Zhan; Connie J Kim; Kiera Clayton; Hanqi Zhao; Erika Lee; Jin Chao Cao; Blake Ziegler; Alexander Gregor; Feng Yun Yue; Sanja Huibner; Sonya MacParland; Jordan Schwartz; Hai Han Song; Erika Benko; Gabor Gyenes; Colin Kovacs; Rupert Kaul; Mario Ostrowski
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

10.  Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy.

Authors:  Christian Prebensen; Andreas Lind; Anne-Ma Dyrhol-Riise; Dag Kvale
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.